LL-37
Status
No approved product. No FDA-approved labeling exists. Not an approved medicine for any indication.
What it is
A human antimicrobial peptide studied for infection and wound models.
What published research measured
The human cathelicidin antimicrobial peptide, a component of innate immunity with direct antibacterial activity and broader roles in wound healing, angiogenesis and immune signalling. The basic science is extensive and well regarded. Translation has been difficult, and the reasons are instructive: LL-37 is cytotoxic to human cells at concentrations not far above its antimicrobial range, it is inactivated by serum, and its immunomodulatory effects run in both directions — elevated LL-37 is implicated in the pathology of psoriasis, rosacea and some autoimmune processes, where it forms complexes with self-DNA that drive interferon responses. Clinical work has been limited to local application, including a phase 1/2 trial of topical LL-37 in venous leg ulcers. Systemic administration in humans has not been established as safe.
Source
Phase 1/2 trial of topical LL-37 in venous leg ulcers
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.